Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and fatal disease with a complicated and challenging diagnosis. With increasing prevalence, this functional impairment of the lungs primarily occurs in individuals ≥ 50 years of age with a mortality rate of nearly 50% in the first 2 ½ - 3 ½ years post-diagnosis. Many barriers to accurate diagnosis exist, including overlapping symptoms with COPD and CHF, and underestimation of symptoms by both clinicians and patients. Recent studies and international guidelines advocate the importance of a multidisciplinary team approach in the initial diagnostic assessment of patients with suspected IPF. Furthermore, treatment is challenging given the heterogeneity in disease progression among individual patients.
This Best Practice® program will review the updated international guidelines for diagnosis and treatment, including advances in the pharmacological management of IPF. Practical strategies that can be implemented to improve the quality of care will be presented with a special emphasis on the role of the multidisciplinary team for improving diagnosis, coordination of care, communication and support of patients with IPF.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Instructions for This Activity and Receiving Credit
This program is directed toward pulmonologists, radiologists, primary care physicians, physician assistants, nurse practitioners, nurses, other healthcare providers interested in IPF.
Upon completion of this program, participants will be able to:
Steven D. Nathan, M.D.
Medical Director, Advanced Lung Disease and Lung Transplant Program
Inova Fairfax Hospital
Falls Church, Virginia
Disclosure: Grant/Research Support: Boehringer-Ingelheim; Consultant: Boehringer-Ingelheim, Roche-Genentech, aTyr Pharma, Bellerophon Therapeutics, Inc., Bayer Pharma; Speaker's Bureau: Boehringer-Ingelheim, Roche-Genentech; Stock/Shareholder: N/A
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
This program is jointly provided by Global Education Group and Physicians’ Education Resource®, LLC. AMA PRA Category 1 Credit™ is provided by Global Education Group.
This program has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians’ Education Resource®, LLC (PER®). Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this live program for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the program.
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational program for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the program.
This program has been planned and implemented in accordance with the accreditation standards of the American Association of Nurse Practitioners (AANP) through joint providership of Global Education Group and PER®. Global Education Group is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number: 1561024. This program is approved for 1.0 contact hour(s) which includes 0.0 hour(s) of pharmacology.
Activity ID #2468E.
This program was planned in accordance with AANP CE standards and policies.
For information about the approval and accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
There is no fee for this educational program.
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this program to disclose any real or apparent conflict of interest they may have as related to the content of this program. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
This CME/CE program may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE program is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or of the company that provided commercial support for this program.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this program is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this program should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018